Australian nanovaccine to protect against country's worst cattle virus

May 5, 2011, University of Queensland

A world-first cattle vaccine based on nanotechnology could provide protection from the Bovine Viral Diarrhoea Virus (BVDV), which costs the Australian cattle industry tens of millions of dollars in lost revenue each year.

The new BVDV vaccine that constitutes a from the virus loaded on , has been shown to produce an against the industry's most devastating virus.

A group of Brisbane scientists has shown that the BVDV nanoformulation can be successfully administered to animals without the need of any additional helping agent making a new ‘nanovaccine' a real possibility for Australian industries.

Scientists Dr. Neena Mitter and Dr. Tim Mahony from the Queensland Alliance for Agriculture and Food Innovation (QAAFI) a UQ Institute recently established in partnership with the Queensland Department of Employment Economic Development and Innovation (DEEDI), partnered with nanotechnology experts Professor Max Lu and Associate Professor Shizang Qiao from the UQ Australian Institute of Bioengineering & Nanotechnology (AIBN) to develop the vaccine.

Dr. Neena Mitter said the multidisciplinary team applied the latest in nanotechnology to develop a safe and effective vaccine that has the potential to be administered more readily and cost effectively than traditional vaccines by using nanoparticles as the delivery vehicles.

“The vaccine is exciting as it could feasibly enable better protection against the virus, can be stored at room temperature and has a long shelf life,” said Dr. Mitter.

According to Dr. Mahony, BVDV is of considerable concern with regard to the long-term profitability of cattle industries across Australia. Cattle producers can experience productivity losses of between 25 and 50 per cent following discovery of BVDV in previously uninfected herds.

“In Queensland alone the beef cattle industry is worth approximately $3.5 billion per year and the high-value feedlot sector experiences losses of over $60 million annually due to BVDV-associated illness,” he said.

Further trials of the nanovaccine will now be conducted with plans to develop a commercial veterinary product in the near future.

Bovine Viral Diarrhoea Virus (BVDV), also known as Bovine Pestivirus, is a viral infection of cattle present in feedlots and beef and dairy herds in Australia. Clinical signs exhibited by infected animals include , respiratory infections, infertility and abortion.

Persistently infected (PI) animals are the principal way BVDV is spread and maintained within a herd. Infection of a foetus with BVDV between 0 and 125 days of gestation can result in the birth of a PI animal that carries the virus for life and is responsible for spread of the virus.

PI shed and spread the BVDV through saliva, nasal secretions, faeces, urine, tears, milk, semen, vaginal discharges, placenta and birth fluid. It can take as little as 1 hour of direct contact with a PI animal to transmit BVDV to an uninfected animal.

Explore further: New test will help identify viral cattle disease

Related Stories

New breakthrough in fight against lethal CCHF virus

May 17, 2010

Crimean-Congo haemorrhagic fever (CCHF) virus is a rare but serious human infection that causes internal bleeding, organ failure and ultimately death. Scientists writing in the Journal of General Virology have developed a ...

Scientists Develop Vaccine Against Deadly Viruses

October 4, 2006

Scientists from the Uniformed Services University of the Health Sciences (USU), in collaboration with counterparts from the Australian Animal Health Laboratory (AAHL), have developed a vaccine to fight two deadly animal viruses ...

Viral life cycle of malignant catarrhal fever explained

April 5, 2010

The mysterious life cycle of a sheep virus that causes malignant catarrhal fever (MCF) has been discovered by Agricultural Research Service (ARS) scientists and their university collaborators—the first step in developing ...

New fowlpox vaccine available

October 26, 2007

A new vaccine developed by CSIRO Livestock Industries to help control the common poultry disease, fowlpox, has been registered for commercial use by one of Australia’s leading animal health companies, Intervet Australia ...

Recommended for you

Team invents method to shrink objects to the nanoscale

December 13, 2018

MIT researchers have invented a way to fabricate nanoscale 3-D objects of nearly any shape. They can also pattern the objects with a variety of useful materials, including metals, quantum dots, and DNA.

Engineers produce smallest 3-D transistor yet

December 10, 2018

Researchers from MIT and the University of Colorado have fabricated a 3-D transistor that's less than half the size of today's smallest commercial models. To do so, they developed a novel microfabrication technique that modifies ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet May 05, 2011
This is pretty significant to me, as once this passes all of the preliminary testing, it will provide a much higher level of protection for livestocks and will be eventually applicable as a proof of concept for all types of antibiotics and vaccines.

It will also be a good platform as an animal model for similar medical nanotechnology in humans.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.